Sean Parker (@drsmparker) 's Twitter Profile
Sean Parker

@drsmparker

Consultant Respiratory Physician. Cough specialist. Music. Wine. Hillwalking. Salmon. Views my own.

ID: 2339175896

calendar_today11-02-2014 21:23:13

1,1K Tweet

416 Followers

1,1K Following

Martin Landray (@martinlandray) 's Twitter Profile Photo

Extraordinary: Raoult’s damaging paper on hydroxychloroquine for COVID-19 finally retracted. So grateful to all the people who helped with the RECOVERY trial, allowing us to debunk the myth of hydroxychloroquine for severe COVID-19 science.org/content/articl…

Extraordinary: Raoult’s damaging paper on hydroxychloroquine for COVID-19 finally retracted. 

So grateful to all the people who helped with the RECOVERY trial, allowing us to debunk the myth of hydroxychloroquine for severe COVID-19

science.org/content/articl…
Dr. Maurice Duffy (@drmauriceduffy) 's Twitter Profile Photo

Let Go to Move Forward. Fly "Mistakes are lessons, not anchors. Let go, and let them teach you how to rise." We often chain ourselves to our mistakes, investing energy into defending them because of pride, fear, or a deep reluctance to face the truth. We tell ourselves the

Let Go to Move Forward. Fly
"Mistakes are lessons, not anchors. Let go, and let them teach you how to rise."

We often chain ourselves to our mistakes, investing energy into defending them because of pride, fear, or a deep reluctance to face the truth. We tell ourselves the
Dr Lawrence Patihis, PhD (@lawrencepatihis) 's Twitter Profile Photo

1. A MUST listen. Such a profoundly informative and insightful summary of Christianity by Tom Holland of The Rest Is History in conversation on Honestly with Bari Weiss. Holland identifiess the central idea: "the last shall be first and the first shall be last" open.spotify.com/episode/4rPYZf…

CHEST (@accpchest) 's Twitter Profile Photo

Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy: A Feasibility Study Read more in the December issue of #journal_CHESTPulm: hubs.la/Q030F4_v0 #MedEd #JournalCHEST

Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy: A Feasibility Study

Read more in the December issue of #journal_CHESTPulm: hubs.la/Q030F4_v0
#MedEd #JournalCHEST
NEJM (@nejm) 's Twitter Profile Photo

Depemokimab, an ultra-long-acting biologic agent with enhanced binding affinity for interleukin-5, may improve outcomes in patients with asthma with an eosinophilic phenotype. Research findings are summarized in a new Quick Take video. nej.md/4iMlpsX

Depemokimab, an ultra-long-acting biologic agent with enhanced binding affinity for interleukin-5, may improve outcomes in patients with asthma with an eosinophilic phenotype. Research findings are summarized in a new Quick Take video. nej.md/4iMlpsX
Nicholas Fabiano, MD (@ntfabiano) 's Twitter Profile Photo

Academics are paid nothing for peer review. Yet journals made a total of over $8.3 billion on article processing charges alone between 2019-2023. Make it make sense.

Academics are paid nothing for peer review.

Yet journals made a total of over $8.3 billion on article processing charges alone between 2019-2023. 

Make it make sense.
NorthumbriaNHS (@northumbrianhs) 's Twitter Profile Photo

As part of the lung cancer screening programme, our consultant David Cooper and manager Amy Watkin talked with the Fishermen’s Mission for their latest podcast. This programme is now underway across Northumberland and North Tyneside. Listen via the link in the comments👇

As part of the lung cancer screening programme, our consultant David Cooper and manager Amy Watkin talked with the Fishermen’s Mission for their latest podcast.

This programme is now underway across Northumberland and North Tyneside.

Listen via the link in the comments👇
CHEST® Journal (@journal_chest) 's Twitter Profile Photo

The latest How I Do It article focuses on selecting the right biologic for a patient with severe asthma. Read more in the February issue of the journal CHEST®: hubs.ly/Q038k2XX0 #MedEd #JournalCHEST #Asthma

The latest How I Do It article focuses on selecting the right biologic for a patient with severe asthma. Read more in the February issue of the journal CHEST®: hubs.ly/Q038k2XX0
#MedEd #JournalCHEST #Asthma
David Paton (@cricketwyvern) 's Twitter Profile Photo

Senior NHS Consultants believe the Leadbeater Bill presents both ‘serious moral hazards to consultants’ and could have ‘serious potential adverse impacts’ on health services in the UK.

Senior NHS Consultants believe the Leadbeater Bill presents both ‘serious moral hazards to consultants’ and could have ‘serious potential adverse impacts’ on health services in the UK.
CHEST® Journal (@journal_chest) 's Twitter Profile Photo

Managing Immune Checkpoint Inhibitor #Pneumonitis in the ICU Read the full research in the March issue of #journal_CHESTCritCare: hubs.la/Q03bQVPk0 #MedEd #CHESTCritCare

Managing Immune Checkpoint Inhibitor #Pneumonitis in the ICU

Read the full research in the March issue of #journal_CHESTCritCare: hubs.la/Q03bQVPk0
#MedEd #CHESTCritCare
Tim Stanley (@timothy_stanley) 's Twitter Profile Photo

Yes, there's a Christian revival going on. Pews are fuller and younger, despite the atheist culture, scandal & poor leadership. It's happening because the story of Jesus *is true*. The story speaks for itself in all places, at all times. It eclipses the noise of modern life.

Yes, there's a Christian revival going on. Pews are fuller and younger, despite the atheist culture, scandal & poor leadership. 
It's happening because the story of Jesus *is true*. The story speaks for itself in all places, at all times. It eclipses the noise of modern life.
James D Chalmers (@profjdchalmers) 's Twitter Profile Photo

We did it! Absolutely thrilled to share the results of the ASPEN trial published today in NEJM Brensocatib(10mg and 25mg vs placebo) reduced exacerbations over 52 weeks and slowed lung function decline A new treatment for bronchiectasis patients nej.md/4lBHwUr

We did it! 
Absolutely thrilled to share the results of the ASPEN trial published today in <a href="/NEJM/">NEJM</a> 
Brensocatib(10mg and 25mg vs placebo) reduced exacerbations over 52 weeks and slowed lung function decline
A new treatment for bronchiectasis patients 
nej.md/4lBHwUr
NEJM Evidence (@nejmevidence) 's Twitter Profile Photo

Patients with a COPD flare and blood eosinophils of >300 cells/µl in the prior year received mepolizumab or placebo for 48 weeks, plus exacerbation treatment. The median time to hospitalization or death due to any cause was similar in both groups. eviden.cc/42YLiQt

Patients with a COPD flare and blood eosinophils of &gt;300 cells/µl in the prior year received mepolizumab or placebo for 48 weeks, plus exacerbation treatment. The median time to hospitalization or death due to any cause was similar in both groups. eviden.cc/42YLiQt
Carolyn Novaleski, Ph.D., CCC-SLP (@novaleski) 's Twitter Profile Photo

Integrative literature review on #ChronicCough and #laryngeal hypersensitivity. Relevant connections are made here between #cough & #pain science. By Saint-Jules et al., 2025, Journal of Voice The Voice Foundation ⬇️ bit.ly/4jtBBzj

Integrative literature review on #ChronicCough and #laryngeal hypersensitivity.

Relevant connections are made here between #cough &amp; #pain science.

By Saint-Jules et al., 2025, Journal of Voice <a href="/TVFPhiladelphia/">The Voice Foundation</a> 

⬇️
bit.ly/4jtBBzj
Danny Kruger (@danny__kruger) 's Twitter Profile Photo

"Now, splendidly, everything had become clear. The enemy at last was plain in view, huge and hateful, all disguise cast off. It was the Modern Age in arms." After this week I feel like Evelyn Waugh at the time of the Nazi-Soviet Pact in 1939. The politics of 'progress' has